Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."
The patent covers milk-derived anti-TNF antibodies that are orally administered within a broad dose range for the treatment of inflammatory bowel disease (IBD). The claims also cover use of these antibodies for the treatment of IBD. Importantly, the patent broadly covers Avaxia's lead product, AVX-470, which recently completed a Phase 1b clinical trial in ulcerative colitis.
Barbara S. Fox, Ph.D., Chief Executive Officer of Avaxia, said, "This patent award is an important milestone for our company. This is the first in a series of patents that Avaxia expects to receive on the composition of our lead clinical-stage candidate, AVX-470. Avaxia will continue to build on its strong intellectual property portfolio in the gut-targeted antibody therapeutics field."
Source: Avaxia Biologics, Inc.,